Reduction in Cerebral Atrophy Associated with Ethyl-eicosapentaenoic Acid Treatment in Patients with Huntington's Disease

Author： Puri BK   Bydder GM   Manku MS   Clarke A   Waldman AD   Beckmann CF  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.36, Iss.5, 2008-09, pp. : 896-905

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tetrabenazine: For Chorea Associated with Huntington's Disease

By Scott Lesley J.  

CNS Drugs, Vol. 25, Iss. 12, 2011-12 ,pp. : 1073-1085

Adis International

Access to resources Recommend Favorite

Eicosapentaenoic acid may inhibit vasospasm and cerebral infarction following subarachnoid haemorrhage

By  

Inpharma, Vol. 1, Iss. 1650, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Effects of icosapent ethyl (Eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of rosiglitazone in healthy subjects

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 2, 2015-03 ,pp. : 143-148

John Wiley & Sons Inc

Access to resources Recommend Favorite

A review of the treatment options for Huntington’s disease

By Bonelli Raphael M   Hofmann Peter  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 767-776

Informa Healthcare

Access to resources Recommend Favorite

Neural Transplantation in Patients with Huntington’s Disease

By Rosser A.E.   Dunnett S.B.  

CNS Drugs, Vol. 17, Iss. 12, 2003-01 ,pp. : 853-867

Adis International

Access to resources Recommend Favorite